Bicara Therapeutics (BCAX) Cash from Investing Activities (2023 - 2026)

Bicara Therapeutics has reported Cash from Investing Activities for 4 years, with the latest figure at $100.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities changed N/A year-over-year to $100.9 million; the trailing twelve-month figure through Mar 2026 stood at -$217.5 million (down 324546.27% YoY), and the FY2025 full-year result was -$318.5 million, down 3538266.67% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $100.9 million, up from -$82.3 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $100.9 million in Q1 2026, with the low at -$236.1 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged -$27.2 million across 4 years, with a median of -$29500.0 in 2024.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities surged 90.83% — and 2025, when it sank 2951412.5%.
• Bicara Therapeutics' Cash from Investing Activities stood at -$436000.0 in 2023, then surged by 90.83% to -$40000.0 in 2024, then plunged by 205730.0% to -$82.3 million in 2025, then surged by 222.6% to $100.9 million in 2026.
• The last three Cash from Investing Activities figures came in at $100.9 million (Q1 2026), -$82.3 million (Q4 2025), and -$236.1 million (Q3 2025), per Business Quant data.